GRML Overview

Greenland Mines Ltd, formerly Klotho Neurosciences, Inc., is a natural resources company. The Company is focused is focused on the exploration and development of the Skaergaard Project. It operates with two operating divisions Natural Resources and Cell and Gene Therapy. The Natural Resources division is focused on the exploration and development of the Skaergaard Project in Southeast Greenland, which is undeveloped palladium, gold, and platinum deposits. It operates three Mineral Exploration Licenses (MEL): MEL 2007-01, MEL 2012-25, and MEL 2021-10. The Company holds, through its acquisition of Greenland Mines Corp., an 80% interest in, and option to acquire the remaining 20% of, the Skaergaard Project. The Cell and Gene Therapy division includes the Company's KLTO-202 primary indication for amyotrophic lateral sclerosis (ALS or Lou Gehrig’s Disease).

Wall Street analysts forecast GRML stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GRML is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Greenland Mines Ltd revenue for the last quarter amounts to -9.51M USD, increased 499.40

Greenland Mines Ltd. EPS for the last quarter amounts to -4971143.00 USD, increased 219.95

Greenland Mines Ltd (GRML) has 2 emplpoyees as of June 10 2026.

Today GRML has the market capitalization of 36.26M USD.